Zealand Pharma Reports Significant Financial Results for 2024
Company announcement No. 2 / 2025 introduces the impressive achievements of Zealand Pharma A/S, a biotechnology company concentrated on the innovation of peptide-based medications.
With a dynamic year behind it, Zealand Pharma has made substantial advancements in its differentiated obesity pipeline, laying the groundwork for sustained growth in the upcoming years. As key progress is made in this critical area, the company looks ahead with optimism.
Transformative Achievements in Obesity Drug Development
In 2024, Zealand Pharma celebrated significant clinical advancements within its mid- to late-stage obesity programs. The company highlights positive results from several trials, setting the stage for future endeavors. “This past year has been a turning point for Zealand Pharma, especially as we gathered encouraging data across our clinical trials, while also securing substantial funding for our research initiatives,” emphasized Adam Steensberg, President and Chief Executive Officer.
Key Clinical Trials Show Promising Results
Among the standout achievements are:
- Long-acting amylin analog petrelintide showed positive results in a 16-week Phase 1b trial, paving the way for a broader Phase 2b trial aimed at individuals with overweight or obesity.
- Dapiglutide, a dual GLP-1/GLP-2 receptor agonist, demonstrated encouraging topline results in a 13-week Phase 1b trial, leading to an expansion of this trial to explore higher doses.
- Survodutide, another dual agonist, advanced into a significant Phase 3 clinical program focused on the treatment of MASH, further cementing Zealand Pharma's commitment to addressing complex obesity issues.
Robust Financial Performance
Zealand Pharma’s financial results for 2024 have also reflected a robust commitment to growth:
- Secured an impressive DKK 8.5 billion (approximately USD 1.2 billion) through equity raises, illustrating strong investor confidence.
- Despite net operating expenses climbing to DKK -1,327 million, the company's strategic investments in R&D show promise for long-term success.
- The cash position significantly improved to DKK 9,022 million from DKK 1,633 million in the previous year, providing a stable foundation for upcoming clinical trials and research expenditures.
Looking Ahead: Financial Guidance for 2025
Zealand Pharma is gearing up for an exciting 2025. The company anticipates embarking on several large Phase 2b trials, laying the groundwork for its wholly-owned obesity programs. Financial guidance suggests a net operating expenses range between DKK 2,000 – 2,500 million, primarily driven by research investments focused on innovative peptide therapeutics related to obesity.
Continued Development in Obesity Treatments
The pipeline for obesity treatments remains promising with the planned initiation of:
- A major Phase 2b trial for petrelintide, aimed at broadening this medication's application among individuals with obesity and type 2 diabetes.
- Further trials for dapiglutide, ensuring it is positioned for optimum results as higher doses are explored.
- Ongoing research for survodutide, where partnerships with Boehringer Ingelheim continue to enhance the scope of potential treatments available for patients.
Expanding into Rare Diseases and Chronic Inflammation
Besides the focus on obesity, Zealand Pharma shows commitment to advancing therapies for rare diseases, such as congenital hyperinsulinism (CHI) and short bowel syndrome (SBS). By addressing these serious health concerns, Zealand Pharma demonstrates its dedication to improving patient outcomes across different therapeutic areas.
Ongoing Commitment to Sustainability
In 2024, Zealand Pharma put a refined sustainability strategy into action, emphasizing environmental responsibility and strategic growth. Moving forward, the company plans to further strengthen its sustainability initiatives while achieving a notable increase in employee engagement and decreasing turnover rates, showcasing its commitment to not only patients but also to its workforce.
Join Zealand Pharma's Upcoming Conference Call
Zealand Pharma invites stakeholders to join its conference call to discuss the financial results and strategic plans outlined for the coming year. Key executives will be present to share insights into the clinical advancements and business operations that drive future success.
Frequently Asked Questions
What were Zealand Pharma's significant achievements in 2024?
In 2024, Zealand Pharma successfully advanced drugs in its obesity pipeline and raised substantial funding for ongoing research and development.
How did the company's financial position change in 2024?
The cash position improved dramatically to DKK 9,022 million from DKK 1,633 million, allowing for increased investment in R&D.
What trials are Zealand Pharma launching in 2025?
Zealand Pharma plans to launch multiple Phase 2b trials focusing on its obesity pipeline, including studies involving petrelintide and dapiglutide.
How does Zealand Pharma integrate sustainability into its strategy?
The company has launched a refined sustainability strategy, focusing on climate change mitigation and continued employee engagement.
Where can I find more information about Zealand Pharma?
For further details about Zealand Pharma's operations and drug candidates, visit their official website.
